Sharmilla Kanagasundram1, Farhanaz Amini2. 1. 1Department of Psychological Medicine, Faculty of Medicine, University Malaya, 50603 Kuala Lumpur, Malaysia. 2. School of Healthy Aging, Medical Aesthetics and Regenerative Medicine, University College Sedaya International (UCSI), Jalan Menara Gading 1, Taman Connaught, 56000 Kuala Lumpur, Selangor Malaysia.
Abstract
BACKGROUND: Allogeneic hematopoietic stem cell transplantation (allo-HSCT) can cure leukaemia. However, long term complications of post transplantation interfere with the patients' full recovery. The objective of this review was to identify the various long term complications and to assess their individual prevalences. METHODS: Electronic databases including PubMed, Google Scholar and Cochrane were searched for years 2004-2017. The keywords used were leukaemia, allogenic stem cell transplantation, prevalence, side effects, long term, delayed, adverse effects, complications and outcome. RESULTS: A total of ten articles were included for analysis. There were 5 prospective studies, 3 retrospective studies and 2 cross sectional studies. A total of 40,069 patients, (20,189 males and 17,191 females) participated in these 10 studies. The gender of 2689 patients were not disclosed. Most common late complications and prevalence were chronic graft versus host disease (43% at 5 years post HSCT), secondary tumor (21% at 20 years post HSCT), hypothyroidism (11% at 15 years), bronchiolitis obliterans (9.7% at 122 days), cardiovascular disease (7.5% at 15 years) and avascular necrosis (5.4% at 10 years). The prevalence of azoospermia was 71.1% and depression, 18%. For the latter two conditions no time limit was available. Follow up duration ranged from 2 years till 30 years post HSCT. CONCLUSION: While allogenic stem cell transplantation is an effective cure for leukaemia, the procedure is associated with complications that can have their onset many years after the procedure.
BACKGROUND: Allogeneic hematopoietic stem cell transplantation (allo-HSCT) can cure leukaemia. However, long term complications of post transplantation interfere with the patients' full recovery. The objective of this review was to identify the various long term complications and to assess their individual prevalences. METHODS: Electronic databases including PubMed, Google Scholar and Cochrane were searched for years 2004-2017. The keywords used were leukaemia, allogenic stem cell transplantation, prevalence, side effects, long term, delayed, adverse effects, complications and outcome. RESULTS: A total of ten articles were included for analysis. There were 5 prospective studies, 3 retrospective studies and 2 cross sectional studies. A total of 40,069 patients, (20,189 males and 17,191 females) participated in these 10 studies. The gender of 2689 patients were not disclosed. Most common late complications and prevalence were chronic graft versus host disease (43% at 5 years post HSCT), secondary tumor (21% at 20 years post HSCT), hypothyroidism (11% at 15 years), bronchiolitis obliterans (9.7% at 122 days), cardiovascular disease (7.5% at 15 years) and avascular necrosis (5.4% at 10 years). The prevalence of azoospermia was 71.1% and depression, 18%. For the latter two conditions no time limit was available. Follow up duration ranged from 2 years till 30 years post HSCT. CONCLUSION: While allogenic stem cell transplantation is an effective cure for leukaemia, the procedure is associated with complications that can have their onset many years after the procedure.
Entities:
Keywords:
Allogenic stem cells; Chronic graft; Late complications; Leukaemia
Authors: S Yoshihara; U Tateishi; T Ando; H Kunitoh; H Suyama; Y Onishi; R Tanosaki; S Mineishi Journal: Bone Marrow Transplant Date: 2005-06 Impact factor: 5.483
Authors: M Robin; P Guardiola; A Devergie; M Yeshurun; S Shapiro; H Esperou; P Ribaud; V Rocha; E Gluckman; G Socié Journal: Leukemia Date: 2005-09 Impact factor: 11.528
Authors: Linus H Santo Tomas; Fausto R Loberiza; John P Klein; Peter M Layde; Randolph J Lipchik; J Douglas Rizzo; Christopher N Bredeson; Mary M Horowitz Journal: Chest Date: 2005-07 Impact factor: 9.410
Authors: H J Kolb; G Socié; T Duell; M T Van Lint; A Tichelli; J F Apperley; E Nekolla; P Ljungman; N Jacobsen; M van Weel; R Wick; M Weiss; H G Prentice Journal: Ann Intern Med Date: 1999-11-16 Impact factor: 25.391
Authors: Marco Mielcarek; Paul J Martin; Wendy Leisenring; Mary E D Flowers; David G Maloney; Brenda M Sandmaier; Michael B Maris; Rainer Storb Journal: Blood Date: 2003-03-27 Impact factor: 22.113
Authors: Hao Dai; Olaf Penack; Aleksandar Radujkovic; David Schult; Joshua Majer-Lauterbach; Igor Wolfgang Blau; Lars Bullinger; Sihe Jiang; Carsten Müller-Tidow; Peter Dreger; Thomas Luft Journal: Bone Marrow Transplant Date: 2021-01-30 Impact factor: 5.483